“…Preclinical studies showing disease response to MEK inhibition have led to multiple clinical trials in NF1-related lesions [98,99]. Targeting RAS-downstream pathway signaling may provide opportunities for synergy across NF1 manifestations, as shown preclinically with MEK inhibition in plexiform neurofibromas, gliomas, and bone pathology [100][101][102]. To date, at least four MEK inhibitors have progressed to clinical trials in NF1; mirdametinib (formerly PD-0325901), trametinib (GSK1120212 Mekinist), binimetinib (ARRY-438162, MEK 162), and selumetinib (AZD6244).…”